Kyverna Therapeutics, Inc. financial data

Symbol
KYTX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
5980 Horton Street, Suite 550, Emeryville, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.15K %
Debt-to-equity 14 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 43.2M shares
Common Stock, Shares, Outstanding 43.2M shares
Weighted Average Number of Shares Outstanding, Basic 43.2M shares +6393%
Weighted Average Number of Shares Outstanding, Diluted 43.2M shares +6393%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 29.2M USD +114%
General and Administrative Expense 9.58M USD +263%
Operating Income (Loss) -38.8M USD -138%
Nonoperating Income (Expense) 4.28M USD +424%
Net Income (Loss) Attributable to Parent -34.5M USD -123%
Earnings Per Share, Basic -0.8 USD/shares +96.6%
Earnings Per Share, Diluted -0.8 USD/shares +96.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 105M USD +356%
Marketable Securities, Current 217M USD
Cash, Cash Equivalents, and Short-term Investments 322M USD
Assets, Current 325M USD
Property, Plant and Equipment, Net 3.15M USD
Operating Lease, Right-of-Use Asset 7.15M USD
Other Assets, Noncurrent 1.88M USD
Assets 339M USD
Accounts Payable, Current 9.93M USD
Liabilities, Current 31M USD
Operating Lease, Liability, Noncurrent 4.97M USD
Other Liabilities, Noncurrent 296K USD
Liabilities 36.5M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax 153K USD
Retained Earnings (Accumulated Deficit) -226M USD
Stockholders' Equity Attributable to Parent 303M USD
Liabilities and Equity 339M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -25.5M USD -123%
Net Cash Provided by (Used in) Financing Activities 338M USD
Net Cash Provided by (Used in) Investing Activities -123M USD -1000%
Common Stock, Shares Authorized 490M shares
Common Stock, Shares, Issued 43.2M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 190M USD +9137%
Interest Paid, Excluding Capitalized Interest, Operating Activities 44K USD 0%
Operating Lease, Liability 7.97M USD
Payments to Acquire Property, Plant, and Equipment 543K USD +1839%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -34.3M USD -122%
Lessee, Operating Lease, Liability, to be Paid 8.87M USD
Property, Plant and Equipment, Gross 6.5M USD
Operating Lease, Liability, Current 3M USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.05M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 3.56M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 903K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 446K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Operating Lease, Payments 811K USD +34.7%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 482K USD +22.3%
Share-based Payment Arrangement, Expense 3.41M USD +555%
Interest Expense 39K USD -15.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares